drugset
drugset / Trial / NCT02020512

A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension

NCT02020512 ↗

Phase 4 Completed 87 enrolled Allergan
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate 0.03% bimatoprost in the treatment of primary open angle glaucoma and ocular hypertension.

Timeline

Start
2011-07
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Bimatoprost Other / unclassified 0.03 % Other

Indications

ocular hypertension open-angle glaucoma